Valuation: AP Biosciences, Inc.

Market Cap 1.34TCr 42Cr 37Cr 35Cr 32Cr 59Cr 4.03TCr 60Cr 416.61Cr 161.51Cr 2.05TCr 157.87Cr 154.41Cr 6.66TCr P/E 2024
-8.86x
P/E 2025 -34.4x
Enterprise Value 1.23TCr 39Cr 34Cr 32Cr 29Cr 54Cr 3.69TCr 55Cr 381.95Cr 148.07Cr 1.88TCr 144.74Cr 141.57Cr 6.1TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.82%
Yield 2024 *
-
Yield 2025 -
1 day+1.48%
1 week+14.17%
Current month+39.37%
1 month+34.98%
3 months+37.00%
6 months-24.31%
Current year-23.89%
1 week 114
Extreme 114
137.5
1 month 93
Extreme 93
137.5
Current year 86.1
Extreme 86.1
236
1 year 86.1
Extreme 86.1
236
3 years 36.3
Extreme 36.3
236
5 years 36.3
Extreme 36.3
236
10 years 36.3
Extreme 36.3
236
Manager TitleAgeSince
Chief Executive Officer - 27/05/2013
Director of Finance/CFO - 18/10/2022
Chief Administrative Officer - 18/10/2022
Director TitleAgeSince
Director/Board Member - 09/11/2022
Director/Board Member - 04/06/2019
Director/Board Member - 04/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%+14.17%+23.98%+137.44% 42Cr
+0.06%+6.49%+60.29%+111.13% 7.42TCr
+0.07%-3.57%+34.57%+75.40% 5.96TCr
-2.05%-3.46%-18.60%+352.20% 2.58TCr
-2.39%+2.74%+0.19%-5.91% 2.47TCr
-0.87%+1.25%+21.66%-9.88% 2.09TCr
+1.29%-2.49%+152.11%+333.06% 1.53TCr
-2.44%-0.09%+42.50%+164.11% 1.41TCr
-3.91%-4.91%-14.10%+779.68% 1.31TCr
-1.12%-3.04%+15.72%+234.56% 1.19TCr
Average -0.83%+0.69%+31.83%+217.18% 2.6TCr
Weighted average by Cap. -0.61%+0.72%+36.34%+161.42%

Financials

2024 2025
Net sales - -
Net income -42Cr -1.33Cr -1.17Cr -1.1Cr -1Cr -1.87Cr -127.41Cr -1.89Cr -13Cr -5.11Cr -65Cr -4.99Cr -4.89Cr -210.61Cr -44Cr -1.4Cr -1.23Cr -1.15Cr -1.06Cr -1.97Cr -134.05Cr -1.99Cr -14Cr -5.38Cr -68Cr -5.25Cr -5.14Cr -221.58Cr
Net Debt -147.07Cr -4.63Cr -4.06Cr -3.82Cr -3.49Cr -6.52Cr -443.25Cr -6.57Cr -46Cr -18Cr -225.99Cr -17Cr -17Cr -732.71Cr -111.14Cr -3.5Cr -3.07Cr -2.88Cr -2.64Cr -4.93Cr -334.95Cr -4.97Cr -35Cr -13Cr -170.77Cr -13Cr -13Cr -553.68Cr
Logo AP Biosciences, Inc.
AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.
Employees
-
Date Price Change Volume
23/26/23 NT$137.00 +1.48% 4,76,937
22/26/22 NT$135.00 0.00% 6,26,964
21/26/21 NT$135.00 +2.27% 9,62,362
18/26/18 NT$132.00 +6.45% 12,16,424
17/26/17 NT$124.00 +3.33% 17,92,434
  1. Stock Market
  2. Stocks
  3. 6945 Stock